04/21/2026
The Association for Clinical and Translational Science (ACTS), a non-profit membership association of translational scientists from the nation’s leading academic medical centers, honored its Fellows at Translational Science 2026.
UM Pharmacology is pleased to announce that Michael Holinstat, PhD was recognized as a 2026 Fellow of ACTS.
This year, ACTS launched the Fellows of ACTS (FACTS) program. FACTS is a premier membership program for individuals who have made substantial contributions to and service within the clinical and translational science field. FACTS recognizes those who are an essential part of the clinical and translational community. This inaugural application process was rigorous and competitive, with 36 individuals selected from ACTS’ almost 6,000-person membership.
"The Fellows of ACTS program recognizes those whose impact on the clinical and translational space and the Association for Clinical and Translational Science is undeniable. The fellowship celebrates the work of the entire translational science community—from researchers to administrative staff. These fellows and their contributions truly embody the values and mission of ACTS for innovation, team science and community. We are pleased to celebrate their achievements and impact at Translational Science 2026” said ACTS President Allan R Brasier, MD.
The Association for Clinical and Translational Science (ACTS) uniquely provides an outstanding platform for enhancing education, research, and public policy related to clinical and translational science. ACTS members consist of leaders, investigators, and trainees from academic medical centers, government, industry, and philanthropy. ACTS focuses on four realms: research, education, advocacy, and mentoring. Additional information is available at the ACTS website at www.actscience.org.